Dr. Gary Novack receives ARVO Drug Development Award

Gary D. Novack, Ph.D., received the Association for Research in Vision and Ophthalmology (ARVO)’s Dr. Roger Vogel award for drug development at the May 2018 annual meeting.  He is shown here receiving the award from Paul Sternberg, M.D., ARVO Foundation President.   This award honors Dr. Roger Vogel, who was in the ophthalmic pharmaceutical business for almost 30 years and led the development of many of the medicines now used by ophthalmologists. The award is given annually to an ARVO member whose research furthers the development of pharmaceutical treatments for ophthalmic diseases.

Dr. Novack states “Roger Vogel was my competitor, my client, my colleague and my friend for decades”.  I am honored to be recognized by ARVO with this award named for him.”

At this annual meeting, Dr. Novack also spoke in a Members-in-Training session on drug development – specifically, how to file an Investigational New Drug exemption with the FDA.  He also presented a poster on the safety findings of a novel ocular hypotensive drug.

 

Dr. Novack receives ARVO Roger Vogel award from Dr. Paul Sternberg

University of California, Davis School of Veterinary Medicine Ophthalmology Grand Rounds

In April 2018, the UC Davis School of Veterinary Medicine hosts joint grand rounds with the UCD Medical Center ophthalmologists at the Gourley Clinical Teaching Facility at the University of California School of Veterinary Medicine. This included lectures and live animal labs.  Dr. Novack, shown here next to visiting lecturer Tom Kern DVM of Cornell, was a participant in this annual event.  More generally, UC Davis takes advantage of ophthalmologists in both the medical and veterinary schools for frequent interaction on the optimal way to treat patients and research novel therapies.  Dr. Novack is a faculty member of the Department of Ophthalmology at the UC Davis School of Medicine.

Photo by Don Preisler/UCDavis © 2018 UC Regents

Sonoma Eye 2018 – Foster Ophthalmic Immunology Society

Dr. Novack presented two oral papers at Sonoma Eye 2018, the second annual event held by the Foster Ophthalmic Immunology Society.  One invited presentation was a brief summary of his 30-year perspective on how to evaluate a potential new therapy.  The other dealt with the issue of drop size in ophthalmic medications – is it an issue or a non-issue.  He had previously published on this issue. The meeting was a small, potent gathering of colleagues, allowing the opportunity to scientific interaction ala ARVO in the Sarasota days of the last century.

 

Gary D. Novack at Sonoma Eye 2018

 

 

 

 

Myopia Society Meeting in Japan

Dr. Novack gave a presentation at the Second Annual Myopia Society of Japan on 24 November 2017.   This was a joint symposium between the Myopia Society Japan and Eye & Contact Lens.  The topic was “Controlling Myopia Progression: Where Do We Stand Today?”.  In the concluding presentation of the event, Dr. Novack spoke about what it would in time and risk to develop a novel pharmacological treatment to prevent the development of myopia in children.  A photo is provided.  Dr. Novack is in the center of the back row.  Also shown are Penny Asbell MD (Icahn School of Medicine) and Kazuo Tsubota, M.D. (Keio University).

Presentations at the AAO 2017

Dr. Novack will be giving several presentations at the Annual Meeting of the American Academy of Ophthalmology in New Orleans in November 2017.  On 9 November, he will lead a breakfast with FDA at the OIS AAO.  On 11 November, he will give a talk at the Glaucoma Sub-specialty day on New Molecules in Glaucoma Development.  On 14 November, he will give a talk on “An update on newly FDA-approved drugs and new drugs in clinical trials” at the Prevent Blindness America symposium.  Finally, he will be part of a course on “Empowering glaucoma patients to take better care of themselves.”

American Academy of Ophthalmology – 2017 – Presentations

Dr. Novack is giving a number of presentations at the upcoming American Academy of Ophthalmology annual meeting in New Orleans.  On 9 November, he will chair a breakfast session at [email protected].  On 11 November, he will be presenting “New Molecules in Clinical Development” at the Glaucoma sub-specialty day.  On 14 November, he will be presenting a talk on “Newly FDA-approved drugs and new drugs in clinical trials” in a glaucoma meeting sponsored by Prevent Blindness America.  Also on 14 November, he will be part of a group of distinguished faculty teaching a course on “Empowering glaucoma patients to take better care of themselves”.